Please login to the form below

Not currently logged in
Email:
Password:

Abraxane

This page shows the latest Abraxane news and features for those working in and with pharma, biotech and healthcare.

Ipsen reports positive phase 3 data for Onivyde in pancreatic cancer

Ipsen reports positive phase 3 data for Onivyde in pancreatic cancer

11.1 months compared to 9.2 months for patients treated with the standard regimen of Bristol-Myers Squibb’s Abraxane (nab-paclitaxel) plus gemcitabine.

Latest news

More from news
Approximately 14 fully matching, plus 40 partially matching documents found.

Latest Intelligence

  • Immuno-oncology in 2019: the rapid evolution continues Immuno-oncology in 2019: the rapid evolution continues

    An FDA ruling on Tecentriq in combination with carboplatin and nab-paclitaxel (Abraxane) as a first-line treatment for patients with metastatic non-squamous NSCLC (based on the IMpower130 trial) is

  • Chinese biotech’s global ambitions Chinese biotech’s global ambitions

    Meanwhile, BeiGene entered into a strategic global collaboration with Celgene in 2017, gaining the rights to Celgene’s Abraxane Revlimid and Vidaza in China, while Celgene gained an option to market

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest from PMHub

  • Marketing strategy in complex environments

    cells. A good example of this is the combined use of  Abraxane and  gemcitabine in the treatment of  metastatic adenocarcinoma of the pancreas – Abraxane helps to inhibit cancer cell growth, and

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
Frontera Group

A leading global patient-activation group - comprising of a digital insight consultancy, creative activation agency. Our foundations lie in behavioural...

Latest intelligence

Virtual Steering Committee & Peer Influence Program
In this customer story, we describe the methodology and results of our client’s ongoing Virtual Steering Committee & Peer Influence program....
Meeting healthcare’s rising challenges
The journey to discover novel therapies through digital innovation and ensure scientific advances achieve their potential...
Report gives insights to address gaps in HCP engagement
How does Pharma-HCP engagement need to evolve in today's digital landscape?...